Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.71 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 3/20 | 0.50 |
| ▸ | AKT2 | P31751 | 2/20 | 0.50 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 3/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778030 | 0.92 | HDAC8 (0.85) | HDAC8MDM2AKT1AKT2AKT3 | |
| SCHEMBL4779328 | 0.89 | HDAC8 (0.71) | HDAC8AKT1AKT2AKT3HDAC3 | |
| SCHEMBL4778400 | 0.88 | HDAC8 (0.56) | HDAC8MDM2AKT1AKT2AKT3 | |
| SCHEMBL4770799 | 0.85 | HDAC8 (0.63) | HDAC8PARP1ALDH1A1MEN1KMT2A | |
| SCHEMBL19887507 | 0.83 | HDAC8 (1.00) | HDAC8MDM2AKT1AKT2AKT3 | |
| SCHEMBL4909543 | 0.83 | HDAC8 (1.00) | HDAC8MDM2AKT1AKT2AKT3 | |
| SCHEMBL17549802 | 0.83 | HDAC8 (1.00) | HDAC8MDM2AKT1AKT2AKT3 | |
| SCHEMBL16380911 | 0.82 | HDAC8 (0.61) | HDAC8AKT1AKT2AKT3HDAC3 | |
| SCHEMBL4778446 | 0.81 | HDAC8 (0.60) | HDAC8AKT1AKT2AKT3MC4R | |
| SCHEMBL4773293 | 0.81 | HDAC8 (0.51) | HDAC8AKT1AKT2AKT3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | HDAC8 16/4885MDM2 3744/4885AKT1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.